

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

# **ProductInformation**

## 5-Fluoro-5'-deoxyuridine

Product Number **F 8791**Store at Room Temperature

## **Product Description**

Molecular Formula: C<sub>9</sub>H<sub>11</sub>FN<sub>2</sub>O<sub>5</sub> Molecular Weight: 246.2 CAS Number: 3094-09-5

Synonym: 5'dFUrd, doxifluridine

5-fluoro-5'-deoxyuridine (5'dFUrd) is an antitumor agent that has been widely investigated in a variety of cancer studies. These include mouse cachexia, human breast cancer, and mouse bladder cancer.

The antineoplastic properties of 5'dFUrd occur upon conversion of the 5'dFUrd to 5-fluorouracil by the enzyme thymidine phosphorylase. 5' 5'dFUrd is also an intermediate in the three-stage enzymatic conversion of capecitabine to 5-fluorouracil. 5'dFUrd has been reported to inhibit DNA synthesis through inhibition of thymidylate synthetase, in a manner analogous to the activity of 5-fluorouracil.

In NIH-3T3 lines transformed by the H-ras (S2-721) and trk (106-632) oncogenes, the sensitivity of these cells to 5'dFUrd is notably enhanced. <sup>8</sup> 5'dFUrd has been shown to enhance uptake of daunorubicin in multidrug-resistant cells. <sup>9</sup> The pharmacokinetics and bioavailability of 5'dFUrd in cancer patients have been investigated. <sup>10</sup>

An HPLC assay for 5'dFUrd and its related metabolites has been published.<sup>11</sup> An analysis of 5'dFUrd and its metabolites by <sup>19</sup>F-NMR has been published.<sup>12</sup>

#### **Precautions and Disclaimer**

For Laboratory Use Only. Not for drug, household or other uses.

## **Preparation Instructions**

This product is soluble in water (50 mg/ml), yielding a clear, colorless solution.

#### References

- Armstrong, R.D., and Diasio, R.B., Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine. Cancer Res., 40, 3333-3338 (1980).
- Tanaka, Y., et al., Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res., 50, 4528-4532 (1990).
- Fujimoto-Ouchi, K., et al., Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models. Clin. Cancer Res., 7, 1079-1086 (2001).
- Ikemoto, S., et al., Augmentation of antitumor activity of 5'-deoxy-5-fluorouridine by thymosin fraction 5 in mouse bladder cancer cells in vitro and in vivo. Cancer Lett., 145, 121-126 (1999).
- Eda, H., et al., Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32, 333-338 (1993).
- Miwa, M., et al., Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur. J. Cancer, 34, 1274-1281 (1998).
- 7. Armstrong, R.D., et al., Mechanism of cytotoxic activity of 5'-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., **11**, 102-105 (1983).
- 8. Peters, G.J., et al., Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int. J. Cancer, **54**, 450-455 (1993).
- Van der Heyden, S., et al., 5'-Deoxy-5fluorouridine increases daunorubicin uptake in multidrug-resistant cells and its activity is related with P-gp 170 expression. Jpn. J. Cancer Res., 85, 13-16 (1994).

- Van der Heyden, S.A., et al., Pharmacokinetics and bioavailability of oral 5'-deoxy-5-fluorouridine in cancer patients. Br. J. Clin. Pharmacol., 47, 351-356 (1999).
- 11. Sommadossi, J.P., et al., Kinetics and metabolism of a new fluoropyrimidine, 5'-deoxy-5-fluorouridine, in humans. Cancer Res., **43**, 930-933 (1983).
- 12. Malet-Martino, M.C., et al., New approach to metabolism of 5'-deoxy-5-fluorouridine in humans with fluorine-19 NMR. Cancer Chemother. Pharmacol., **13**, 31-35 (1984).

GCY/AJH 11/02